Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Nano Dimension Ltd - ADR — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Nano Dimension Ltd - ADR trades at $1.39 (market cap $306.41M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 9.3× Nano Dimension Ltd - ADR's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| DYN | NNDM | |
|---|---|---|
Market Cap | $2.86B | $306.41M |
Volume | 3,341,579 | 1,735,346 |
Sector | Health | Technology |
52-Week High | $26.78 | $2.14 |
52-Week Low | $14.60 | $1.21 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $2.18B | -$98.44M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Nano Dimension (NNDM) trades at $1.41, down 6.62% with a bearish technical signal. The company shows revenue growth to $102.44M in 2025 but deepens net losses to -$293.30M, resulting in a negative net margin of -286.32%. Recent strategic moves include appointing a new board member and cost-saving initiatives targeting $25M in annual cash burn reduction. The stock faces significant selling pressure with 18 sell signals versus 7 buy signals in technical indicators.
The outlook remains challenging with persistent losses despite revenue growth. Investment opportunity exists in the company's cash position of $757.96M and low EV/EBITDA of 0.19, but risks include negative cash flow, leadership transitions, and shareholder activism. The stock trades near support levels with institutional sentiment cautious amid ongoing restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
